Human Genome Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Human Genome Sciences, Inc.
Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.
The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.